ES8705897A1 - Un metodo para producir una proteina capaz de modular la actividad fisiologica de celulas que tienen receptores de diazepam. - Google Patents

Un metodo para producir una proteina capaz de modular la actividad fisiologica de celulas que tienen receptores de diazepam.

Info

Publication number
ES8705897A1
ES8705897A1 ES551233A ES551233A ES8705897A1 ES 8705897 A1 ES8705897 A1 ES 8705897A1 ES 551233 A ES551233 A ES 551233A ES 551233 A ES551233 A ES 551233A ES 8705897 A1 ES8705897 A1 ES 8705897A1
Authority
ES
Spain
Prior art keywords
polypeptides
antibodies
derivable
brain
polypeptide factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES551233A
Other languages
English (en)
Other versions
ES551233A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/694,712 external-priority patent/US4714683A/en
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of ES8705897A1 publication Critical patent/ES8705897A1/es
Publication of ES551233A0 publication Critical patent/ES551233A0/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/16Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D323/00Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/804Radioisotope, e.g. radioimmunoassay
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/811Test for named disease, body condition or organ function
    • Y10S436/813Cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/828Cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/839Nerves; brain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

METODO PARA PRODUCIR UNA PROTEINA MODULADORA DE LA ACTIVIDAD FISIOLOGICA DE CELULAS. COMPRENDE: A) EXTRAER TEJIDO CEREBRAL DE UNA SOLUCION ETANOLICA ACIDA; B) REEXTRAER EL EXTRACTO ETANOLICO EN UNA MEZCLA DE CLOROFORMO Y AGUA ACIDIFICADA; C) RECOGER UNA FASE SUPERIOR ACUOSA DE LA MEZCLA; D) DIALIZAR LA FASE DE LA ETAPA C), PARA OBTENER UNA FRACCION PROTEINICA BRUTA; E) SEPARAR LA FRACCION PROTEINICA BRUTA EN FRACCIONES DE DIFERENTE PESO MOLECULAR, POR CROMATOGRAFIA DE PERMEACION EN GEL; F) CONTROLAR LA ACTIVIDAD COMPETIDORA DE BENZODIAZEPINA Y LA ACTIVIDAD INHIBIDORA DE CRECIMIENTO, PARA DETERMINAR LA IDENTIDAD DE LAS FRACCIONES QUE LLEVEN POLIPEPTIDO; Y G) SEPARAR DICHO POLIPEPTIDO MEDIANTE CROMATOGRAFIA LIQUIDA CON FASE INTERNA. SE UTILIZAN COMO ANSIOLITICOS, ANTICONVULSIVOS Y SEDANTES.
ES551233A 1985-01-25 1986-01-24 Un metodo para producir una proteina capaz de modular la actividad fisiologica de celulas que tienen receptores de diazepam. Expired ES8705897A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/694,712 US4714683A (en) 1985-01-25 1985-01-25 Polypeptide tumor inhibitors and antibodies thereto
US06/766,864 US4806492A (en) 1985-01-25 1985-08-15 Polypeptide tumor inhibitors and antibodies thereto

Publications (2)

Publication Number Publication Date
ES8705897A1 true ES8705897A1 (es) 1987-05-16
ES551233A0 ES551233A0 (es) 1987-05-16

Family

ID=27105426

Family Applications (2)

Application Number Title Priority Date Filing Date
ES551233A Expired ES8705897A1 (es) 1985-01-25 1986-01-24 Un metodo para producir una proteina capaz de modular la actividad fisiologica de celulas que tienen receptores de diazepam.
ES557400A Expired ES8802538A1 (es) 1985-01-25 1987-02-16 Un metodo de producir una proteina capaz de modular la actividad fisiologica de celulas que tienen un receptor de diazepam

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES557400A Expired ES8802538A1 (es) 1985-01-25 1987-02-16 Un metodo de producir una proteina capaz de modular la actividad fisiologica de celulas que tienen un receptor de diazepam

Country Status (8)

Country Link
US (2) US4777270A (es)
EP (1) EP0210233A4 (es)
JP (9) JPH064672B2 (es)
AU (1) AU589598B2 (es)
ES (2) ES8705897A1 (es)
MX (1) MX163576B (es)
PT (1) PT81916B (es)
WO (2) WO1993013089A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011777A (en) * 1985-01-25 1991-04-30 Oncogen Vectors encoding brain derivable polypeptide factors
US4935442A (en) * 1985-02-28 1990-06-19 Pfizer Inc. Tetrahydrofuran-containing macrocyclic polyether carboxylic acids
JP2690956B2 (ja) * 1987-08-22 1997-12-17 三井東圧化学株式会社 生体由来のタンパク質
WO1990004263A1 (en) * 1988-10-14 1990-04-19 Matsushita Electric Industrial Co., Ltd. Image sensor and method of producing the same
DK169306B1 (da) * 1989-06-14 1994-10-10 Af 18 Juni 1990 As Middel til fjernelse eller inaktivering af uønskede komponenter i blod eller andre ekstracellulære legemsvæsker samt fremgangsmåde til fremstilling af dextran-O-carbonyl-benzo-18-crown-6 og af dextran-hydroxyethylbenzo-18-crown-6
US5142068A (en) * 1989-10-06 1992-08-25 Virginia Tech Intellectual Properties, Inc. Mono- and di(functionally-substituted phenylene) semi-rigid crowns and processes for making
US5648340A (en) * 1991-10-31 1997-07-15 Barnea; Eytan R. Gestational agents for controlling cell proliferation
US5160483A (en) * 1991-05-07 1992-11-03 The University Of Tennessee Research Corporation Fragment of TNF-α for promoting wound healing
US5758132A (en) * 1995-03-29 1998-05-26 Telefonaktiebolaget Lm Ericsson Clock control system and method using circuitry operating at lower clock frequency for selecting and synchronizing the switching of higher frequency clock signals
CA2386199A1 (en) * 1999-10-05 2001-04-12 Curagen Corporation Endozepine-like polypeptides and polynucleotides encoding same
WO2006005590A1 (en) * 2004-07-12 2006-01-19 Geneprot Inc. Polypeptide for the treatment of neurological disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130580C (es) * 1966-05-16
US3580889A (en) * 1967-08-17 1971-05-25 Du Pont Vulcanization accelerators of polycyclic ethers for fluorinated polymers
US3622577A (en) * 1968-11-08 1971-11-23 Du Pont Trimerization of organic isocyanates
US3686225A (en) * 1969-04-01 1972-08-22 Du Pont Complexes of polyether compounds and ionic compounds
US3687978A (en) * 1969-08-06 1972-08-29 Du Pont Macrocyclic polyether compounds
US3839557A (en) * 1972-01-24 1974-10-01 Lilly Co Eli Antibiotics monensin and a204 for improving ruminant feed efficiency
US3965116A (en) * 1974-09-12 1976-06-22 The Regents Of The University Of California Multioxymacrocycles
GB1524711A (en) * 1975-03-14 1978-09-13 Shell Int Research Macrocyclic polyethers
US4152335A (en) * 1975-03-14 1979-05-01 Shell Oil Company Macrocyclic polyethers
US4024158A (en) * 1975-09-19 1977-05-17 E. I. Du Pont De Nemours And Company Aroylcrownethers
US3997565A (en) * 1975-09-19 1976-12-14 E. I. Du Pont De Nemours And Company Acylcrownether oximes and oxime ethers
SU644789A1 (ru) * 1976-08-02 1979-01-30 Отдел Биоорганической Химии Ан Узбекской Сср Диацильные производные 2,3,11,12дибензо-1,4,7,10,13,16-гексаоксациклооктадока-2,11-диена, в качестве регул тора ионной проницаемости биологических мембран
SU732270A1 (ru) * 1977-07-07 1980-05-05 Институт химии Уральского научного центра АН СССР Комплексные соединени дибензо-18- краун-6 с сол ми металлов как катализаторы реакции переэтерификации и поликонденсации в синтезе полиэтилентерефталата
SU726096A1 (ru) * 1977-07-07 1980-04-05 Институт химии Уральского научного центра АН СССР Амиды дибензо-18-краун-6, как промежуточные продукты дл синтеза их комплексов с сол ми металлов
US4186175A (en) * 1978-01-25 1980-01-29 Phillips Petroleum Company Crown ether uranyl halide complexes
IT1134503B (it) * 1980-11-28 1986-08-13 Proter Spa Composti della diclorodietilaminofenilalanina ad azione antitumorale
SU981318A1 (ru) * 1981-07-31 1982-12-15 Предприятие П/Я А-1997 Способ получени производных 2,5,8,15,18,21-гексаоксатрицикло/20,4,0,09,14/ гексакозана
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
JPS6019719A (ja) * 1983-07-15 1985-01-31 Asahi Chem Ind Co Ltd 抗腫瘍活性を有する蛋白質

Also Published As

Publication number Publication date
JPH03193800A (ja) 1991-08-23
MX163576B (es) 1992-06-03
WO1986004239A1 (en) 1986-07-31
JPH03169896A (ja) 1991-07-23
JPH03164183A (ja) 1991-07-16
ES557400A0 (es) 1988-07-01
JPH03178999A (ja) 1991-08-02
ES8802538A1 (es) 1988-07-01
WO1993013089A1 (en) 1993-07-08
JPH03172183A (ja) 1991-07-25
JPH03155787A (ja) 1991-07-03
JPH064672B2 (ja) 1994-01-19
PT81916B (pt) 1987-11-30
JPH03169892A (ja) 1991-07-23
AU589598B2 (en) 1989-10-19
PT81916A (en) 1986-02-01
EP0210233A1 (en) 1987-02-04
ES551233A0 (es) 1987-05-16
JPH03163098A (ja) 1991-07-15
EP0210233A4 (en) 1989-11-07
US4777270A (en) 1988-10-11
US4806492A (en) 1989-02-21
JPS62501841A (ja) 1987-07-23
AU5359586A (en) 1986-08-13

Similar Documents

Publication Publication Date Title
EP0653940A4 (en) GLIALMITOGENIC FACTORS, THEIR PRODUCTION AND USE.
DK375283A (da) Dna-sekvenser, rekombinations-dna-molekyler samt fremgangsmaader til fremstilling af kvaegvaeksthormonlignende polypeptider
CY2586B2 (en) Modulators of the function of FAS/APO1 receptors
EP0376746A3 (en) Gene family of tumor-associated antigens
MD430C2 (ro) Procedeu de obţinere a interferonelor leucocitare umane
ES8802538A1 (es) Un metodo de producir una proteina capaz de modular la actividad fisiologica de celulas que tienen un receptor de diazepam
EP0585257A4 (en) DNA AND AMINO ACID SEQUENCE SPECIFIC TO NATURAL K KILLER CELLS.
DK54184A (da) Dna-sekvenser, rekombinations-dna-molekyler samt fremgangsmaader til fremstilling af human (interleukin) to-lignende polypeptider
AU3460289A (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
EP0365525A4 (en) Lymphocyte inhibition by hla peptides
DK358787D0 (da) Vaekstfaktor, nucleotidsekvens kodende for vaekstfaktoren ekspressionsplasmid omfattende nucleotidsekvensen,vaert indeholdende plasmidet protein fremstillet af vaerten, fremgangsmaade til fremstilling af vaekstfaktoren og farmaceutisk praeparat indeholdendevaekstfaktoren
DK0625157T3 (da) Blodplade-GPIIIaP1A1- og -P1A2-epitoper og fremstilling og anvendelse deraf
DE68917154D1 (de) C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.
EP0712928A3 (es)
EP0293079A3 (en) Chlamydia vaccine
IL129139A0 (en) Vertebrate smoothened proteins
EP0160486A3 (en) Monoclonal antibodies
ES2002915A6 (es) Un procedimiento para la preparacion de un peptido de veneno de serpiente que detiene el crecimiento.
EP0207165A4 (en) POLYPEPTIDE SECRETION VECTOR, MICROORGANISMS TRANSFORMED BY SAID VECTOR, AND PROCESS FOR THE PREPARATION OF POLYPEPTIDES WITH SAID MICROORGANISMS.
EP1026237A3 (en) Tau/neurofilament protein kinases pk40 & pk36
EP0317279A3 (en) Peptides for use in the purification of factor viii
AU580035B2 (en) Coking residuum in the presence of hydrogen donor
AU1321988A (en) The cloning of malaria-specific dna sequences: isolation of the gene for the 140 kd protein
DE3671603D1 (de) Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.
AT384824B (de) Alkoholische getraenke mit hohem eiweissgehalt und verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19990405